key: cord-0960206-bybc7cws
authors: Shamsi, T. S.; Imam, M.; Khawaja, S.; Naz, A.; Siddiqi, A. Q.; Nafees, T. S.; Younas, A.; Shamsi, U.; Shabir, I.; Ahmed, S.; Tariq, N.; Tariq, S.
title: Performance Assessment of First-Generation AntiSARS-CoV-2 Serological Assays
date: 2020-09-24
journal: nan
DOI: 10.1101/2020.09.22.20197046
sha: 0c874302fff1b8224b9448f489411cfa3dfac300
doc_id: 960206
cord_uid: bybc7cws

The clinical and epidemiological use of SARS-CoV-2 antibody assays is under debate with urgent need to validate and verify the performance of SARS-CoV-2 serologic assays. We aim to assess the clinical and analytical performance of three commercial serological assays of SARS-CoV-2, comparing three anti-SARS-CoV-2-IgG ELISA and identifying the seroconversion and seroprevalence in our population. A cross sectional study conducted from April 2020 to July 2020 at National Institute of Blood disease and Bone Marrow Transplantation Karachi, Pakistan with sample size of 404, enrolled consecutively. Participants were categorized into four groups namely convalescent plasmadonors (CPDs n=239), health care professionals (HCPs n=44), healthy blood donors (HBDs n=70) and from community (n=51). We evaluated the performance of Elecsys anti-SARS-CoV-2 electrochemiluminescence (ECLIA) assay on Cobas-e411 by Roche, three qualitative anti-SARS-CoV-2-IgG enzyme linked imunosorbant assay (ELISA) by (Generic assays, Euroimmun & Omega diagnostics) ,one quantitative ELISA assay by AESKU Diagnostics and two immune chromatography(ICT) kits namely InstaTestTM by CORTEZ and TEST IT by TURKLAB. From total 404 subjects, 322 (83.5%) were males. Mean age was 36.79 plus minus 11.95 years. Among 239 in CPDs group, 202(84.5%) showed positive antibodies by ECLIA. The qualitative anti-SARS-CoV-2 IgG ELISA was positive in 174 (72.8%) and quantitative IgG in 180(75.3%) with mean titer of 56.7 plus minus 39.7 U/ml. Sensitivity and specificity of ECLIA were 97.44& 99%, ELISA by Generic assays were 67.85% and 89.9%; Euroimmun had 90.38% and 94.9%; Omega Diagnostics 96.4% and 95% and the AESKULISA 93.75% and 100% respectively. Seroconversion was found to be 53.8% and 77.77% within 7 -8 days and 12 to 14 days post onset of symptoms respectively. ICT had more specificity but less sensitivity. Seroprevalence was found to be 84.5%, 40.9% and 21.4% in CPDs, HCPs and HBDs respectively. The Roche ECLIA, qualitative ELISA by Omega Diagnostics & Euroimmun showed higher sensitivity as well as higher specificity. Quantitative ELISA has higher specificity and relatively high sensitivity. Significant numbers of COVID patients do not have detectable antibodies by all assays.

The global pandemic of COVID-19 caused by Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2) affected Pakistan in mid-March 1 and till mid-July 2020, a total of 254,000 cases were diagnosed and 5,500 (2.1%) deaths reported 2 . According to the Center of Disease Control (CDC), the recommended method for the diagnosis of COVID-19 is to detect the RNA of SARS-CoV-2 by real time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) with samples collected from nasopharynx and / or oropharynx 3, 4 .Commercial manufacturers developed serological testing kits using different methodologies 5 .FDA gave approval for the use of these kits as Emergency Use Authorization (EUA) 6 . Verification and validation of these assays is required to achieve the clinical accuracy of test results 7, 8 .

There are several advantages of serological testing. Pre analytical and analytical parts of serological assays have comparatively easy sample collection, simple to analyzeand requires less technical expertise as compared to nucleic acid detection. Serological testing can be performed in basic and small clinical laboratory settings 8, 9 . Post analytical important uses of antibody testing include; to determine the exposure of this disease among tested population, to assess the immune response against this virus and to identify the actual number of people who had acquired this virus but were asymptomatic therefore they didn't get tested on RT-PCR. The results of this testing will be significant for epidemiological studies, disease surveillance and later in monitoring of response to the vaccine 9, 10 . It plays vital role for identification of convalescent plasma donors for therapeutic use in treating moderate to severely ill COVID-19 patients 10 .

There are several methodologies available for the antibody testing which include immune chromatographytechnique(ICT),electrochemiluminescenceimmunoassay(ECLIA),chemiluminee (CLIA) and enzyme linked immunosorbant assay (ELISA) 8, 11 etc. To-date very little data

Study Design: A cross sectional study conducted from April 2020 to June 2020 in Karachi, Pakistan after the approval from institution's ethical review committee. Informed written consent was taken from all study subjects.Non-probability consecutive sampling technique was used for sampling. Three milliliter (ml) blood was collected in gel vacutainer from all subjects or serological testing and nasopharyngeal swab was taken for anti-SARS-CoV-2 RT-PCR testing.

We divided our subjectsin following four groups shown in Table no 1. The anti-SARS-CoV-2 antibodies were tested by ECLIA, ICT and by ELISA. The ECLIA and ICT were qualitative while ELISA was performed on both qualitative as well as quantitative kits. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 24, 2020. . https://doi.org/10.1101/2020.09.22.20197046 doi: medRxiv preprint community closed acquaintances to get them tested for COVID-19, along with them walk-in patients who were tested for PCR and anti SARS-CoV-2 IgG simultaneously were also taken in this group.

Healthy blood donors (HBDs)

Regular blood donors were recruited in this group and after their consent we tested them for anti-SARS-CoV-2antibodies.

For analytical performance, repeatabilitydone using known negative samples, pre-pandemic preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We evaluated the performance of three different serological assays infourdifferentgroups. This study included convalescent plasma donors'whorecovered from COVID-19 infection.The performance characteristics of different kits e.g., sensitivity claimed by their manufacturers, fell short since our calculated sensitivities were below thatofthe manufacturers' claim. This finding is in accordance with an Australian report published on 29 th April 2020 that assessed post-market validation of three serological assays for COVID-19 where they tested the serological assays on CPDs and found out their own diagnostic performance for each kit 14 .

Out of the three methodologies, ECLIA assay had sensitivity 97.44%, qualitative ELISA by Omega diagnostics had 96.4% while other two qualitative ELISA had lower sensitivity. This may be due to the fact that electrochemiluminescence assay detects total antibodies (including IgG) against SARS-CoV-2 while ELISA is only IgG specific.

Mei San Tang et al compared Abbott Chemiluminescenceassay and ELISA within 5 days of onset of symptoms, none of the immunoassays was able to detect the antibodies 9 . This leads to an important observation that when to test for the presence of antibodies against SARS-CoV-2 antibodies in our population.The samples which were taken from HCPs and community within 3 to 5 days post the onset of symptoms did not show antibody positivity on either assay. This finding is in contrast with the manufacturer's claim that for ECLIA by Roche which showed 65.5% (CI 56%-74%) sensitivity when tested within 6 days PCR confirmation. None the less, gold standard for the diagnosis of acute SARS-CoV-2 infection is RT-PCR and we will need larger cohorts of patients to identify correct time for using serological assays in our population.

We found important and interesting finding in our study, out of 239 CPDs the 37 (15.5%) did not develop antibodies against SARS-CoV-2 virusbyany of the testing method i.e. ECLIA, All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The heathyblood donors had no symptoms of COVID-19 infection, they were healthy and active;a quarter of them seroconverted against COVID-19. This is a significant finding as it highlights the prevalence of this disease in general population. This observation has not been reported until now. We have also correlated the results of ECLIA and ELISA in our groups of CP donors and healthy blood donors which is showing positive correlation between these two assays.

Limitation of study was that we could not perform RT-PCR of healthy blood donors and ELISA of health care professionals and people from community due to cost limitation. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 24, 2020. . https://doi.org/10.1101/2020.09.22.20197046 doi: medRxiv preprint

Progress of COVID-19 Epidemic in Pakistan

Laboratory diagnosis of COVID-19: current issues and challenges

The role of antibody testing for SARS-CoV-2: is there one

Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food

Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

Interpreting diagnostic tests for SARS-CoV-2

Clinical Performance of Two anti-SARS-CoV-2 Serologic Assays

All rights reserved. No reuse allowed without permission

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea

Antibody responses to SARS-CoV-2 in patients with COVID-19

Post-market validation of three serological assays for COVID-19

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Diagnostic performance of COVID-19 serology assays

A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction